Myriad Genetics reports Prolaris Prostate Cancer Prognostic Test study published

Myriad Genetics announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk, or CCR, score can accurately predict the benefit of adding androgen deprivation therapy, or ADT, to radiation therapy, or RT, in men with localized prostate cancer. Guidelines currently recommend adding ADT to RT in certain patients with localized prostate cancer. While ADT can be effective at slowing the progression of prostate cancer, it can also be associated with significant side effects, such as bone and muscle loss, weight gain, and increased cardiovascular risk. The study – first presented as a poster at the 2023 American Society of Clinical Oncology, or ASCO, annual conference by Jonathan Tward – examined two cohorts of male patients tested with the Prolaris Prostate Cancer Prognostic Test either clinically or through retrospective studies. The study demonstrated that patients with a Prolaris CCR score below the multimodal threshold have only a 0.86% average reduction in 10-year risk of metastasis if they elect to pursue multimodal therapy by adding ADT to RT. However, patients with a Prolaris CCR score above the multimodal threshold can reduce risk of metastasis by 8.19% on average by adding ADT to RT.